Compare SSYS & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSYS | AURA |
|---|---|---|
| Founded | 1989 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.7M | 713.4M |
| IPO Year | 2012 | 2021 |
| Metric | SSYS | AURA |
|---|---|---|
| Price | $8.05 | $7.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $12.33 | ★ $20.00 |
| AVG Volume (30 Days) | 427.1K | ★ 461.3K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | $3.23 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.34 | $4.73 |
| 52 Week High | $12.78 | $9.54 |
| Indicator | SSYS | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 47.79 |
| Support Level | $7.44 | $6.61 |
| Resistance Level | $8.24 | $7.04 |
| Average True Range (ATR) | 0.28 | 0.26 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 49.44 | 35.00 |
Stratasys Ltd offers polymer-based 3D printing solutions for designers, engineers, manufacturers, dental and medical professionals, and others. Its 3D printing systems utilize the firm's patented extrusion-based FDM, inkjet-based PolyJet, powder-bed-based SAF, photopolymer-based P3, and Neo stereolithography technologies to enable the production of prototypes, tools, and manufactured goods directly from 3D CAD files or other 3D content. The company's solutions portfolio comprises 3D printing systems, consumables, software, paid parts, and professional services, allowing end-users to effectively print 3D models, tools, and parts. Geographically, it generates maximum revenue from the United States, followed by Europe, Middle East and Africa, Asia-Pacific, and other regions.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.